The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.
Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.
A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic in Uganda, were the three winners of Sandoz’s competition to imp